Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.

Scientific reports·2026
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Diabetes, obesity & metabolism·2026
Same author

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

Molecular metabolism·2025
Same author

Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

Molecular metabolism·2025
Same journal

m6A modification of LINC00458 enhances HMOX1 stability via ELAVL1 recruitment to promote ferroptosis and aggravate asthma.

Molecular immunology·2026
Same journal

Overexpression of Hes1 inhibits cigarette smoke-induced mitochondrial apoptosis in AT2 cells by activating the Pgc-1α/Tfam signaling pathway.

Molecular immunology·2026
Same journal

Progesterone promotes favorable pregnancy outcomes in recurrent spontaneous, abortion by attenuating NK Cell overactivation and upregulating the cAMP/PKA/CREB signaling axis.

Molecular immunology·2026
Same journal

Oleanolic acid alleviates hepatic fibrosis by inhibiting liver macrophage recruitment and polarization.

Molecular immunology·2026
Same journal

Cordycepin attenuates diabetic nephropathy by dual-pathway activation of TFEB to restore autophagy and ameliorate podocyte injury.

Molecular immunology·2026
Same journal

Endothelial-derived TWEAK drives granulosa cell apoptosis in PCOS via the Fn14-oxidative stress axis.

Molecular immunology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Recent developments in low molecular weight complement inhibitors.

Hongchang Qu1, Daniel Ricklin, John D Lambris

  • 1Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, 401 Stellar Chance, 422 Curie Blvd., Philadelphia, PA 19104, USA.

Molecular Immunology
|October 6, 2009
PubMed
Summary
This summary is machine-generated.

Low molecular weight complement inhibitors show promise for treating diseases linked to overactive immune responses. These targeted therapies, including peptides and small molecules, are advancing in clinical trials.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Related Experiment Videos

Last Updated: Jun 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • The complement system is crucial for innate immunity and pathogen defense.
  • Dysregulated complement activation contributes to autoimmune diseases, inflammation, and neurodegeneration.
  • Targeting complement offers therapeutic potential for various pathological conditions.

Purpose of the Study:

  • To review low molecular weight complement inhibitors.
  • To focus on inhibitors targeting C1, C3, and anaphylatoxin receptors.
  • To highlight therapeutic strategies for complement-mediated diseases.

Main Methods:

  • Literature review of complement inhibitor research.
  • Analysis of small molecule and peptide inhibitors.
  • Examination of inhibitors targeting specific complement cascade components.

Main Results:

  • Numerous low molecular weight complement inhibitors have been developed.
  • Inhibitors demonstrate efficacy in in vitro and in vivo studies.
  • Several inhibitors are progressing through clinical trials with positive outcomes.

Conclusions:

  • Low molecular weight complement inhibitors represent a promising therapeutic avenue.
  • Targeted inhibition of complement components like C1 and C3 holds significant potential.
  • Further clinical development is warranted for these novel therapies.